Long-term outcomes of IgA nephropathy in China
Nephrology Dialysis Transplantation · 30.05.2025 · 40 (6) · 1137-1146
DOI: 10.1093/ndt/gfae252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 18.11.2024. Verfasst von Xue Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Proteinuria, Kidney Failure, Chronic. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Background
The long-term prognosis of immunoglobulin A nephropathy (IgAN) and the optimal target for proteinuria treatment remain controversial. This study, utilizing a large prospective cohort from China, aims to assess the long-term outcomes of IgAN and to explore the definition of proteinuria remission.
Methods
We enrolled 2141 patients with biopsy-proven IgAN, all with at least 12 months of follow-up, from a prospective IgAN cohort at Peking University First Hospital. We utilized Kaplan–Meier analysis, Cox regression and an estimated glomerular filtration rate (eGFR) slope calculated via a linear mixed model to investigate kidney outcomes.
Results
The median (Q1, Q3) baseline proteinuria was 1.26 (0.65, 2.40) g/day, and the eGFR was 80 (52, 103) mL/min/1.73 m2. After a mean follow-up of 5.8 (±4.4) years, 509 (24%) patients progressed to end-stage kidney disease (ESKD). The median kidney survival time was 12.4 years, the annual event rate of ESKD was 41.1 per 1000 person-years and the 15-year kidney survival rate was 40%. Time-averaged proteinuria level was strongly associated with kidney failure (adjusted hazard ratio 1.76, 95% confidence interval 1.65 to 1.88). Restriction cubic spline analysis indicated that the risk of ESKD increases rapidly when time-average proteinuria exceeded 0.5 g/day. There was no significant difference in long-term kidney survival between patients with proteinuria <0.3 g/day and those with 0.3–0.5 g/day, with both groups demonstrating a better prognosis.
Conclusion
The long-term outcomes for patients with IgAN under current treatment strategies remain poor, with most progressing to ESKD within 15 years. Patients with time-averaged proteinuria ≥0.5 g/day experience worse kidney outcomes, challenging the previous view that proteinuria <1.0 g/day was associated with a low risk of kidney failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
- Institute of Nephrology, Peking University, Beijing, China.
- Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
- Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.
- The second people's hospital of Shanxi province, Shanxi, China.
ORCID-Profile: Xue Shen
Förderung
- National Natural Science Foundation of China
- Capital's Funds for Health Improvement and Research
- CAMS Innovation Fund for Medical Sciences
- Peking University First Hospital
Zitieren
APA
Shen, X., Chen, P., Liu, M., Liu, L., Shi, S., Zhou, X., Lv, J., & Zhang, H. (2025). Long-term outcomes of IgA nephropathy in China. Nephrology Dialysis Transplantation, 40(6), 1137-1146. https://doi.org/10.1093/ndt/gfae252
Vancouver
Shen X, Chen P, Liu M, Liu L, Shi S, Zhou X, et al. Long-term outcomes of IgA nephropathy in China. Nephrology Dialysis Transplantation. 2025;40(6):1137-1146. doi:10.1093/ndt/gfae252
BibTeX
@article{Shen2025,
author = {Shen, Xue and Chen, Pei and Liu, Muqing and Liu, Lijun and Shi, Sufang and Zhou, Xujie and Lv, Jicheng and Zhang, Hong},
title = {Long-term outcomes of IgA nephropathy in China},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
volume = {40},
number = {6},
pages = {1137--1146},
doi = {10.1093/ndt/gfae252}
}
EUVIMED